Stocktoria
Akari Therapeutics Plc AKTX
Akari Therapeutics Plc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $2.8M | $7.0M | $5.5M | $9.6M | $9.1M | $8.8M | $8.7M | $11.8M | $23.3M | $17.3M |
| SG&A expense | $9.3M | $9.7M | $11.4M | $13.5M | $8.1M | $9.2M | $8.2M | $11.7M | $11.8M | $9.9M |
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$17.2M | -$18.0M | -$17.0M | -$20.8M | -$37.8M | -$27.2M |
| Interest expense | $100,000 | — | — | — | — | — | — | — | $0 | $0 |
| Income tax | -$1.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$17.4M | -$17.1M | -$16.8M | -$20.5M | -$35.4M | -$18.1M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.01 | — | — | — |
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$18.8M | -$17.0M | -$12.9M | -$22.8M | -$31.6M | -$24.6M |
| Free cash flow | — | — | — | — | — | — | -$12.9M | -$22.8M | -$31.6M | -$24.7M |
| Cash & equivalents | $5.2M | $0 | $3.8M | $13.2M | $9.4M | $14.1M | $5.7M | $5.4M | $28.1M | $34.1M |
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M | $14.6M | $6.5M | $8.0M | $29.1M | $45.9M |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M | $5.2M | $6.5M | $4.9M | $11.9M | $11.8M |
| Shareholders' equity | $28.3M | $22.2M | -$229,000 | $1.8M | $5.6M | $9.4M | $7,598 | $4.4M | $22.2M | $34.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.